Institut Pasteur
Paris, FR· latest recorded location
Institut Pasteur is named on 920 US grants and 625 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 920
- Published applications
- 625
- Inventors
- 1,520
- Granted in 2026 so far
- 13
- Most recent grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 3 | 0 |
| 1978 | 2 | 0 |
| 1979 | 3 | 0 |
| 1980 | 5 | 0 |
| 1981 | 2 | 0 |
| 1982 | 3 | 0 |
| 1983 | 3 | 0 |
| 1984 | 5 | 0 |
| 1985 | 10 | 0 |
| 1986 | 3 | 0 |
| 1987 | 7 | 0 |
| 1988 | 4 | 0 |
| 1989 | 8 | 0 |
| 1990 | 6 | 0 |
| 1991 | 14 | 0 |
| 1992 | 6 | 0 |
| 1993 | 12 | 0 |
| 1994 | 15 | 0 |
| 1995 | 6 | 0 |
| 1996 | 13 | 0 |
| 1997 | 29 | 0 |
| 1998 | 42 | 0 |
| 1999 | 47 | 0 |
| 2000 | 37 | 0 |
| 2001 | 43 | 2 |
| 2002 | 25 | 23 |
| 2003 | 35 | 28 |
| 2004 | 25 | 30 |
| 2005 | 16 | 29 |
| 2006 | 32 | 40 |
| 2007 | 22 | 25 |
| 2008 | 31 | 25 |
| 2009 | 24 | 32 |
| 2010 | 38 | 45 |
| 2011 | 22 | 28 |
| 2012 | 21 | 23 |
| 2013 | 31 | 13 |
| 2014 | 29 | 32 |
| 2015 | 19 | 27 |
| 2016 | 27 | 19 |
| 2017 | 25 | 34 |
| 2018 | 23 | 24 |
| 2019 | 21 | 17 |
| 2020 | 18 | 32 |
| 2021 | 21 | 25 |
| 2022 | 20 | 15 |
| 2023 | 19 | 14 |
| 2024 | 23 | 22 |
| 2025 | 12 | 15 |
| 2026 | 13 | 6 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 1,545 documents
- A61KMedicines and medical preparations940
- C07KPeptides914
- C12NMicroorganisms or enzymes816
- A61PTherapeutic uses of medicines757
- G01NInvestigating or analysing materials by determining their chemical or physical properties510
- C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms401
- Y02ATechnologies for adaptation to climate change373
- Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests222
- A01KAnimal husbandry93
- C12YEnzymes69
Recent patents
- Luciferase linked immunosorbent assay6 Oct 2026US 12,753,245 B2
- Antibody blocking human FcγRIIIA and FcγRIIIB4 Aug 2026US 12,698,331 B2
- Method for detecting spatial coupling5 May 2026US 12,620,100 B2
- Interleukin-2 variants with modified biological activity28 Apr 2026US 12,611,445 B2
- Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins28 Apr 2026US 12,612,411 B1
- Use of inhibitors of adam12 as adjuvants in tumor therapies24 Sep 2026US 2026/0286009 A1
- Antibodies against orthohantaviruses27 Aug 2026US 2026/0250362 A1
- Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases6 Aug 2026US 2026/0224687 A1
- Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins6 Aug 2026US 2026/0224755 A1
- Systems and Methods for the Prediction of Post-Operative Cognitive Decline Using Blood-Based Inflammatory Biomarkers6 Aug 2026US 2026/0229316 A1
Most cited
By later US patents
- 2,N.sup.6 -disubstituted and 2,N.sup.6 -trisubstituted adenosine-3'-phosphoramidites528US 4,845,205 A1989
- Multi-penetration vaccination apparatus193US 4,109,655 A1978
- Method of detecting and characterizing a nucleic acid or reactant for the application of this method185US 4,581,333 A1986
- Chromosomal modification involving the induction of double-stranded DNA cleavage and homologous recombination at the cleavage site155US 8,921,332 B22014
- Biocompatible implant for the expression and in vivo secretion of a therapeutic substance151US 5,906,817 A1999